CLDX
Celldex Therapeutics, Inc. NASDAQ Listed May 15, 1986$33.41
Mkt Cap $2.2B
52w Low $20.01
92.2% of range
52w High $34.55
50d MA $32.02
200d MA $28.05
P/E (TTM)
-7.8x
EV/EBITDA
—
P/B
4.2x
Debt/Equity
0.0x
ROE
-49.1%
P/FCF
-10.4x
RSI (14)
66.40
ATR (14)
$1.16
Beta
1.20
50d MA
$32.02
200d MA
$28.05
Avg Volume
878.3K
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Perryville III Building · Hampton, NJ 08827 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -1.15 | -1.18 | -2.9% | 33.32 | +4.9% | +2.0% | -5.0% | -0.9% | +1.6% | -0.2% | — |
| Feb 25, 2026 | AMC | -1.00 | -1.22 | -22.0% | 30.82 | -2.5% | -0.6% | -1.8% | -0.3% | -3.5% | +2.1% | — |
| Nov 10, 2025 | AMC | -0.88 | -1.01 | -14.8% | 22.67 | -1.8% | +7.5% | -0.5% | -2.2% | +7.7% | +1.8% | — |
| Aug 7, 2025 | AMC | -0.86 | -0.85 | +1.2% | 21.21 | -4.4% | -2.6% | -3.1% | +18.9% | +5.0% | -0.2% | — |
| May 8, 2025 | AMC | -0.75 | -0.81 | -8.0% | 19.52 | -6.8% | -6.1% | +10.1% | -2.8% | -3.5% | +6.1% | — |
| Feb 27, 2025 | AMC | -0.73 | -0.71 | +2.7% | 20.31 | -2.0% | +1.3% | -5.9% | +3.4% | +5.5% | +1.1% | — |
| Nov 6, 2024 | AMC | -0.69 | -0.64 | +7.2% | 27.63 | +1.3% | -4.2% | -0.9% | -0.0% | +3.1% | -0.6% | — |
| Aug 8, 2024 | AMC | -0.59 | -0.54 | +8.5% | 32.71 | +0.4% | +0.6% | +1.6% | -0.5% | -2.9% | +2.4% | — |
| May 6, 2024 | AMC | -0.67 | -0.56 | +16.4% | 41.65 | -1.4% | +1.3% | -2.4% | -0.4% | -2.8% | +0.5% | — |
| Feb 26, 2024 | AMC | -0.76 | -0.57 | +25.0% | 48.23 | +1.9% | +5.8% | +0.6% | -6.4% | +7.9% | -2.3% | — |
| Nov 2, 2023 | AMC | -0.67 | -0.81 | -20.9% | 24.01 | +5.8% | +8.2% | +13.0% | -1.1% | -8.7% | -2.7% | — |
| Aug 8, 2023 | AMC | -0.65 | -0.65 | +0.0% | 32.41 | -13.3% | -5.8% | +0.1% | -1.0% | +2.8% | +1.2% | — |
| May 4, 2023 | AMC | -0.63 | -0.62 | +1.6% | 31.49 | +0.1% | +5.7% | +0.2% | -0.7% | +1.3% | -1.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 20 | Barclays | Upgrade | Underweight → Overweight | — | $34.55 | $35.79 | +3.6% | -0.5% | -0.4% | -0.1% | -1.9% | -0.8% |
| Mar 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $30.09 | $29.94 | -0.5% | -0.3% | -3.5% | +2.1% | -0.6% | +0.2% |
| Feb 26 | Stifel | Maintains | Buy → Buy | — | $30.82 | $30.05 | -2.5% | -0.6% | -1.8% | -0.3% | -3.5% | +2.1% |
| Dec 17 | Barclays | Maintains | Underweight → Underweight | — | $26.68 | $26.59 | -0.3% | -3.4% | -1.9% | +1.2% | +6.5% | -2.5% |
| Nov 11 | Barclays | Maintains | Underweight → Underweight | — | $22.67 | $22.26 | -1.8% | +7.5% | -0.5% | -2.2% | +7.7% | +1.8% |
| Sep 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $24.58 | $24.32 | -1.1% | -0.5% | +6.0% | -5.1% | +1.0% | -2.5% |
| Aug 20 | Wells Fargo | Maintains | Overweight → Overweight | — | $24.02 | $21.96 | -8.6% | -13.0% | +5.4% | +2.0% | -2.4% | -0.8% |
| Aug 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.02 | $21.96 | -8.6% | -13.0% | +5.4% | +2.0% | -2.4% | -0.8% |
| Aug 20 | Citigroup | Maintains | Buy → Buy | — | $24.02 | $21.96 | -8.6% | -13.0% | +5.4% | +2.0% | -2.4% | -0.8% |
| Aug 20 | Canaccord Genuity | Maintains | Buy → Buy | — | $24.02 | $21.96 | -8.6% | -13.0% | +5.4% | +2.0% | -2.4% | -0.8% |
| Jun 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.26 | $21.43 | +0.8% | -4.3% | -1.4% | +3.8% | -1.5% | -0.5% |
| Jun 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.35 | $20.21 | -0.7% | +4.5% | -4.3% | -1.4% | +3.8% | -1.5% |
| May 9 | Morgan Stanley | Maintains | Overweight → Overweight | — | $19.52 | $18.20 | -6.8% | -6.1% | +10.1% | -2.8% | -3.5% | +6.1% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.52 | $18.20 | -6.8% | -6.1% | +10.1% | -2.8% | -3.5% | +6.1% |
| May 9 | UBS | Maintains | Buy → Buy | — | $19.52 | $18.20 | -6.8% | -6.1% | +10.1% | -2.8% | -3.5% | +6.1% |
| May 9 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.52 | $18.20 | -6.8% | -6.1% | +10.1% | -2.8% | -3.5% | +6.1% |
| May 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.29 | $20.00 | -1.4% | -9.3% | +2.8% | +3.2% | -6.1% | +10.1% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.57 | $21.27 | +3.4% | -5.9% | +3.4% | +5.5% | +1.1% | -3.1% |
| Mar 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $20.57 | $21.27 | +3.4% | -5.9% | +3.4% | +5.5% | +1.1% | -3.1% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.31 | $19.90 | -2.0% | +1.3% | -5.9% | +3.4% | +5.5% | +1.1% |
| Jan 2 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $25.27 | $25.54 | +1.1% | +2.1% | +4.0% | -0.9% | +3.8% | -3.9% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.38 | $25.18 | -0.8% | -0.9% | -1.5% | +1.5% | +2.1% | -1.0% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.82 | $24.81 | -0.0% | +2.3% | -0.9% | -1.5% | +1.5% | +2.1% |
| Nov 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.98 | $25.00 | +0.1% | +5.7% | -0.7% | +3.1% | +4.1% | -4.9% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.63 | $28.00 | +1.3% | -4.2% | -0.9% | -0.0% | +3.1% | -0.6% |
| Oct 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.95 | $27.29 | +1.3% | +3.8% | -4.0% | -2.0% | -1.0% | -1.5% |
| Aug 12 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $32.92 | $33.13 | +0.6% | +1.6% | -0.5% | -2.9% | +2.4% | +3.3% |
| Aug 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.92 | $33.13 | +0.6% | +1.6% | -0.5% | -2.9% | +2.4% | +3.3% |
| Jul 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $41.99 | $38.30 | -8.8% | -8.5% | -0.9% | -1.5% | -7.4% | -5.9% |
| Jul 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.99 | $38.30 | -8.8% | -8.5% | -0.9% | -1.5% | -7.4% | -5.9% |
| Jul 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.55 | $40.10 | +1.4% | +1.1% | -3.0% | -3.1% | -2.2% | -1.1% |
| Jun 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $34.91 | $35.92 | +2.9% | -0.7% | +3.0% | -1.2% | +2.6% | +0.1% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.30 | $34.20 | +2.7% | +0.5% | -2.1% | +0.8% | +6.4% | +0.5% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.47 | $40.97 | +3.8% | +1.8% | -0.6% | -4.3% | -1.2% | -0.2% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.65 | $41.07 | -1.4% | +1.3% | -2.4% | -0.4% | -2.8% | +0.5% |
| Apr 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.60 | $39.01 | +1.1% | +2.7% | -2.8% | -1.4% | +2.3% | -2.8% |
| Mar 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $41.01 | $41.63 | +1.5% | +2.4% | -1.3% | -1.0% | +1.8% | +0.4% |
| Feb 27 | Guggenheim | Maintains | Buy → Buy | — | $48.23 | $49.13 | +1.9% | +5.8% | +0.6% | -6.4% | +7.9% | -2.3% |
| Nov 10 | Wells Fargo | Upgrade | Underweight → Equal Weight | — | $25.78 | $26.91 | +4.4% | +4.5% | +0.1% | +3.4% | +2.3% | -2.6% |
| Nov 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.98 | $32.98 | +26.9% | +13.0% | -1.1% | -8.7% | -2.7% | +4.5% |
| Nov 3 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $24.01 | $25.40 | +5.8% | +8.2% | +13.0% | -1.1% | -8.7% | -2.7% |
| Oct 12 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $28.01 | $27.81 | -0.7% | -5.4% | -1.3% | +2.4% | -8.1% | -2.5% |
| Sep 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $26.51 | $26.84 | +1.2% | +3.1% | +2.4% | -1.7% | -0.5% | -4.1% |
| Aug 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.43 | $31.44 | +0.0% | -4.1% | -1.0% | +1.2% | +1.3% | -5.2% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.52 | $30.65 | +0.4% | +0.1% | -1.0% | +2.8% | +1.2% | -4.1% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $32.41 | $28.11 | -13.3% | -5.8% | +0.1% | -1.0% | +2.8% | +1.2% |
| Jun 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.80 | $35.65 | +2.4% | +6.6% | +3.2% | -1.8% | -1.9% | -3.2% |
| May 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.18 | $31.29 | +0.4% | +2.0% | +1.0% | +3.3% | +2.5% | +2.8% |
| May 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.49 | $31.52 | +0.1% | +5.7% | +0.2% | -0.7% | +1.3% | -1.5% |
| May 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.49 | $31.52 | +0.1% | +5.7% | +0.2% | -0.7% | +1.3% | -1.5% |
No insider trades available.
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Underwriting / Securities
CLDX entered into an underwriting agreement with Leerink Partners, likely signaling an upcoming secondary offering that could dilute existing shareholders but provide needed capital for operations or acquisitions.
Apr 2
8-K
Celldex Therapeutics, Inc -- 8-K Filing
Celldex Therapeutics' barzolvolimab advanced efficacy data and ahead-of-schedule Phase 3 enrollment completion in chronic spontaneous urticaria suggest positive momentum that could support future regulatory approvals and revenue growth.
Feb 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 3,749,048 | $119M | Reduced | Mar 2026 |
| 2 | Point72 Asset Management | 3,229,939 | $102M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 2,960,895 | $94M | New | Mar 2026 |
| 4 | Braidwell Lp | 1,858,109 | $50M | Added | Dec 2025 |
| 5 | Millennium Management | 1,253,532 | $40M | Added | Mar 2026 |
| 6 | Bellevue Group Ag | 1,200,000 | $38M | Reduced | Mar 2026 |
| 7 | Pictet Asset Management Holding Sa | 968,616 | $26M | Reduced | Dec 2025 |
| 8 | Bank Of America Corp /de/ | 708,647 | $22M | Added | Mar 2026 |
| 9 | Vanguard Portfolio Management Llc | 629,252 | $20M | New | Mar 2026 |
| 10 | Northern Trust Corp | 577,267 | $18M | Added | Mar 2026 |
| 11 | Woodline Partners Lp | 500,127 | $16M | — | Mar 2026 |
| 12 | Morgan Stanley | 571,070 | $16M | Reduced | Dec 2025 |
| 13 | Adar1 Capital Management, Llc | 427,816 | $14M | New | Mar 2026 |
| 14 | Segall Bryant & Hamill, Llc | 346,919 | $11M | New | Mar 2026 |
| 15 | Rosalind Advisors, Inc. | 330,000 | $10M | New | Mar 2026 |
| 16 | Ubs Group Ag | 296,970 | $9M | Reduced | Mar 2026 |
| 17 | Stempoint Capital Lp | 254,267 | $8M | New | Mar 2026 |
| 18 | Algert Global Llc | 215,159 | $7M | Added | Mar 2026 |
| 19 | Nuveen, Llc | 201,949 | $6M | Added | Mar 2026 |
| 20 | Citadel Advisors Llc | 200,612 | $6M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.22B
Enterprise Value
$1.70B
P/E (TTM)
-7.82x
Forward P/E
—
PEG Ratio
-0.12x
P/B
4.21x
P/S
2709.47x
P/FCF
-10.40x
EV/EBITDA
—
Shares Out
66.5M
Financials (TTM)
Revenue
$820K
Net Income
-$283.7M
EBITDA
-$280.3M
Free Cash Flow
-$213.7M
Op Cash Flow
-$210.9M
EPS Basic
$-3.90
EPS Diluted
$-4.27
EPS Forward
$-4.76
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$583.0M
Total Liab.
$55.8M
Total Equity
$527.2M
Cash
$518.6M
LT Debt
$0
Book Value/Sh
$7.93
Debt/Equity
0.00x
Current Ratio
10.49
Quick Ratio
10.49
Returns & Growth
ROE
-49.1%
ROA
-44.4%
ROIC
-53.9%
Rev Growth YoY
-78.6%
EPS Growth YoY
-59.2%
Price Returns
2W
-3.1%
1M
-4.4%
3M
+4.5%
6M
+16.3%
12M
+58.9%
Technicals
52W High
$34.55
52W Low
$20.01
50d MA
$32.02
200d MA
$28.05
RSI (14)
66.40
ATR (14)
$1.16
Beta
1.20
Avg Volume
878K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$45.00
High
$45.00
Low
$45.00
Median
$45.00
Data updated apr 25, 2026 1:37am
· Source: financialmodelingprep.com